McKesson to pay $151M to states to settle inflated price charges
This article was originally published in Scrip
Executive Summary
US drug distributor giant McKesson has agreed to pay $151 million to settle charges of inflating prices of over 1,400 brand-name prescription medications, including Pfizer's Lipitor (atorvastatin) and Forest's Celexa (citalopram), causing 29 states' Medicaid programs to overpay for the drugs.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.